Xilingio 25/5mg Tablet 10s

Xilingio 25 5mg Tablet 10s is a fixed-dose combination medicine specifically designed to improve blood sugar control in adults with Type 2 Diabetes Mellitus. It contains Empagliflozin (an SGLT2 inhibitor) and Linagliptin (a DPP-4 inhibitor), which work together to reduce high blood sugar levels. This dual-action treatment not only helps manage diabetes effectively but also offers significant benefits for cardiovascular health and kidney protection. Healthcare professionals often recommend this combination to enhance glycaemic control when monotherapy is insufficient.

Xilingio 25 5mg Tablet 10s is an advanced, dual-therapy prescription for the long-term management of Type 2 Diabetes Mellitus. This medication combines two distinct mechanisms of action for superior glycaemic control. The first component, Empagliflozin, belongs to the Sodium-Glucose Co-transporter 2 (SGLT2) inhibitor class. It works by blocking SGLT2 in the kidneys, preventing glucose from being reabsorbed back into the bloodstream and increasing glucose excretion via the urine. This leads to a reduction in blood sugar levels and, importantly, has been shown to reduce the risk of cardiovascular events and slow the progression of chronic kidney disease in diabetic patients.

The second component, Linagliptin, is a Dipeptidyl Peptidase-4 (DPP-4) inhibitor. It enhances the body's natural ability to lower blood sugar by increasing the levels of active incretin hormones. These hormones stimulate the pancreas to produce more insulin when blood sugar levels are high and decrease the amount of glucose produced by the liver. The synergistic effect of Empagliflozin and Linagliptin in Xilingio 25 5mg Tablet 10s results in a more comprehensive and sustained reduction in HbA1c levels than either drug alone. Consistent, once-daily use, combined with diet and exercise, is crucial for protecting the heart and kidneys and dramatically lowering the long-term complications of uncontrolled diabetes.

The primary uses of Xilingio 25 5mg Tablet 10s (Empagliflozin 25mg + Linagliptin 5mg) are centred on the treatment and proactive management of Type 2 Diabetes Mellitus:

• Treats Type 2 Diabetes Mellitus in adults to improve blood sugar control.

• Used when diet, exercise, and single-drug therapy (monotherapy) are insufficient to control blood sugar levels.

• Helps reduce the risk of cardiovascular death in adults with Type 2 Diabetes who have established cardiovascular disease.

• Used to protect kidney function by managing the condition in patients with Type 2 Diabetes and chronic kidney disease.

• A key part of a comprehensive diabetes management plan includes diet and physical activity.

Decisive Dual Action for Glycaemic Control:

Xilingio 25 5mg Tablet 10s combines two potent agents, an SGLT2 inhibitor and a DPP-4 inhibitor, to target different pathways of blood sugar regulation. This offers a more comprehensive and sustained reduction in blood glucose levels.

Cardio-Renal Protection:

Empagliflozin, a component of this medicine, has been clinically proven to reduce the risk of cardiovascular death and heart failure hospitalisation, while also slowing the progression of kidney disease in patients with diabetes.

Weight Management Support:

Increased glucose excretion through the urine (due to Empagliflozin) can lead to a modest but beneficial reduction in body weight, which is advantageous for patients with Type 2 Diabetes.

Convenient Once-Daily Dosing:

The combination allows for a single tablet to replace two separate medications, simplifying the treatment regimen and significantly improving patient adherence for better long-term outcomes.

While Xilingio 25 5mg Tablet 10s is generally well-tolerated, some side effects may occur. Most are mild and often lessen as the body adjusts:

Common Side Effects:

• Upper respiratory tract infection (e.g., common cold)

• Urinary tract infections (UTIs)

• Genital fungal infections (e.g., vaginal yeast infection or balanitis)

• Increased urination or thirst

• Headache or joint pain

Less Common/Serious Side Effects (Seek medical attention if you experience):

• Symptoms of a severe allergic reaction (swelling of the face, lips, throat)

• Signs of a UTI that is spreading (fever, back pain)

• Unexplained severe pain or tenderness in the genital or perineal area (Fournier's gangrene)

• Low blood sugar (hypoglycaemia), especially if taken with insulin or sulphonylureas.

Disclaimer: Consult your doctor if any side effects persist or worsen, or if you experience any signs of a severe reaction or infection.

• Take Xilingio 25 5mg Tablet 10s exactly as prescribed by your doctor regarding dosage and duration.

• Swallow the tablet whole with a glass of water. Do not crush, chew, or break it.

• Take the medicine once daily, preferably at the same time each day.

• It can be taken with or without food.

• Do not stop taking this medicine abruptly without consulting your doctor, as this may worsen blood sugar control.

Xilingio 25 5mg Tablet 10s utilises a dual, complementary mechanism to control blood sugar.

1. Empagliflozin (SGLT2 Inhibitor): It blocks the action of the Sodium-Glucose Co-transporter 2 (SGLT2) protein, which is responsible for reabsorbing most of the glucose back into the bloodstream from the kidneys. By blocking this, excess glucose can be removed from the body through the urine, effectively lowering blood sugar levels. This mechanism is independent of insulin.
2. Linagliptin (DPP-4 Inhibitor): It works by inhibiting the enzyme Dipeptidyl Peptidase-4 (DPP-4). The DPP-4 enzyme typically breaks down incretin hormones (GLP-1 and GIP). By blocking DPP-4, Linagliptin increases the level of these active incretin hormones, which then stimulate insulin release from the pancreas and reduce glucagon production from the liver, but only when blood sugar levels are high.

The combined action provides a highly effective and targeted approach to improve the body’s ability to manage glucose.

• Always follow your doctor's prescribed dosage and do not adjust it without consulting your doctor.

• Monitor your blood sugar levels regularly, as advised by your doctor, to ensure the medicine is working effectively.

• Stay well-hydrated throughout the day to reduce the risk of urinary tract or genital infections.

• Inform your doctor immediately if you experience persistent thirst, nausea, abdominal pain, or fatigue, as these could be signs of a serious condition like ketoacidosis.

• Store Xilingio 25 5mg Tablet 10s below 25 degrees Celsius in a cool, dry place.

• Keep the tablets in their original packaging to protect them from heat and moisture.

• Keep the medicine out of the sight and reach of children.

• Do not use the medicine after the expiry date printed on the pack.

Xilingio 25 5mg Tablet 10s is generally safe to take with most foods and can be taken with or without a meal. However, patients with Type 2 Diabetes should be mindful of their overall diet, as confident choices can impact the medicine's effectiveness:

• Alcohol: Avoid or limit alcohol severely, as it can interfere with blood sugar control and increase the risk of low blood sugar or lactic acidosis.

• Excessive Simple Carbohydrates: While the medicine helps, a diet high in simple sugars will counteract its effectiveness in achieving optimal blood sugar control.

• Balanced Diet: Maintain a consistent, balanced diet to support stable blood sugar and overall liver health.

Xilingio 25 5mg Tablet 10s can interact with other medications. Always inform your doctor about all current prescriptions and supplements.

• Insulin and Sulphonylureas (e.g., Glimiperide): The risk of hypoglycaemia (low blood sugar) is significantly increased when taken with these medications. A dose adjustment of insulin or the sulphonylurea may be required.

• Diuretics (Water Tablets): Taking this medicine with diuretics (e.g., Furosemide) can increase the risk of dehydration and low blood pressure due to Empagliflozin's increased urinary output.

• DPP-4 Inhibitors: Avoid taking other medications containing a DPP-4 inhibitor (such as Sitagliptin or Saxagliptin), as this would result in a double dose of Linagliptin.

Patients with certain pre-existing conditions must use Xilingio 25 5mg Tablet 10s with caution and under close medical supervision:

• Severe Kidney Impairment: Empagliflozin's glucose-lowering effect depends on kidney function; monitoring kidney function is essential.

• Liver Disease: Dose adjustments may be necessary for patients with severe liver impairment, as Linagliptin is metabolised via the liver.

• Diabetic Ketoacidosis (DKA) History: Not for use in patients with Type 1 Diabetes or a history of DKA.

• Heart Failure: Can be beneficial in certain patients, but cardiologists must closely monitor its use.

• Chronic Alcoholism: Increases the risk of severe side effects like lactic acidosis.

The standard recommended dosage of Xilingio 25 5mg Tablet 10s (Empagliflozin + Linagliptin) is one tablet once daily. It should be taken at the same time each day, with or without food, as part of your overall diabetes management plan. Your doctor will determine the exact dose based on your individual blood sugar control, existing medical conditions, and response to treatment. Never change your dose or stop the medication without consulting your healthcare provider.

If you miss a dose of Xilingio 25 5mg Tablet 10s, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not double the dose to make up for a missed dose, as this increases the risk of side effects such as low blood sugar. Consistent daily intake is vital for maintaining optimal blood sugar control.